# Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)

> **NCT05351736** · PHASE4 · UNKNOWN · sponsor: **Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico** · enrollment: 10 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lurasidone

## Key facts

- **NCT ID:** NCT05351736
- **Lead sponsor:** Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-26
- **Primary completion:** 2024-01-28
- **Final completion:** 2024-04-28
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05351736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05351736, "Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05351736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*